| Identification | Back Directory | [Name]
4-(1,1,2,2,3,3,4,4,4-nonadeuteriobutyl)-1,2-diphenylpyrazolidine-3,5-dione | [CAS]
1189479-75-1 | [Synonyms]
[2H9]-Phenylbutazone
4-(1,1,2,2,3,3,4,4,4-nonadeuteriobutyl)-1,2-diphenylpyrazolidine-3,5-dione | [Molecular Formula]
C19H11D9N2O2 | [MDL Number]
MFCD09841173 | [MOL File]
1189479-75-1.mol | [Molecular Weight]
317.43 |
| Hazard Information | Back Directory | [Uses]
A non-steroidal anti-inflammatory labelled compound. An inhibitor of cyclooxygenase that is also a substrate for peroxidation by cyclooxygenase. | [Biological Activity]
Phenylbutazone-d9 is intended for use as an internal standard for the quantification of phenylbutazone by GC- or LC-MS. Phenylbutazone is a non-steroidal anti-inflammatory drug and an inhibitor of the peroxidase activity of COX (IC50 = ~100 μM in the presence of hydrogen peroxide).1 It also inhibits prostaglandin I synthase (IC50 = ~25 μM in the presence of hydrogen peroxide). Phenylbutazone (2 mg/kg) reduces increases in type II collagen levels in the inflamed joints of an equine model of LPS-induced acute synovitis.2 Formulations containing phenylbutazone have been used in the treatment of lameness in horses. | [References]
1.Reed, G.A., Griffin, I.O., and Eling, T.E.Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolismMol. Pharmacol.27(1)109-114(1985)
2.de Grauw, J.C., van Loon, J.P.A.M., van de Lest, C.H.A., et al.In vivo effects of phenylbutazone on inflammation and cartilage-derived biomarkers in equine joints with acute synovitisVet. J.201(1)51-56(2014)
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
ChemeGen
|
| Tel: |
18818260767 |
| Website: |
https://www.chemegen.com |
|